Amgen(US:AMGN) Seeking Alpha·2026-03-11 15:52Core Insights - The company exited 2025 with strong momentum, achieving double-digit growth in both revenue and earnings per share, supported by 13 products delivering double-digit growth and 14 products exceeding $1 billion in annual sales [2][3] Group 1: Growth Drivers - The momentum is driven by six key growth drivers: Repatha, EVENITY, TEZSPIRE, rare disease treatments, innovative oncology, and the biosimilars portfolio [3] - Repatha, EVENITY, and TEZSPIRE each grew over 30% year-over-year in 2025, achieving record sales and representing multibillion-dollar global franchises [3] - These medicines address significant unmet medical needs, with millions of patients yet to be treated, indicating strong growth potential not only for 2026 but for the entire decade [3]